Xoma wraps up work on $15M biodefense contract


xoma Xoma Ltd. said Monday it completed its work under a $15 million government biodefense contract.

The Berkeley company (NASDAQ: XOMA) said the National Institute of Allergy and Infectious Diseases (NIAID) gave its final acceptance of the contract, which it awarded to Xoma in March 2005. Xoma developed manufacturing processes for three anti-botulinum neurotoxin monoclonal antibodies.

Xoma won a $16 million follow-on contract in July.

John Castello is Xoma's chairman, president and CEO.

NIAID is part of the National Institutes of Health.